Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar
Ustekinumab, Denosumab And Pertuzumab Biosimilars Progress
Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”
You may also be interested in...
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
With EirGenix about to start Phase III trials for its proposed biosimilar version of Perjeta, the Taiwanese developer says it is negotiating with global firms for rights to the pertuzumab candidate.
Following launches in other key developed markets, Biocon’s plans to break into the US bevacizumab market continue to be frustrated, with further bad news from the US Food and Drug Administration.